Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing

Barry Boland, Wai Haung Yu, Olga Corti, Bertrand Mollereau, Alexandre Henriques, Erwan Bezard, Greg M. Pastores, David C. Rubinsztein, Ralph A. Nixon, Michael R. Duchen, Giovanna R. Mallucci, Guido Kroemer, Beth Levine, Eeva Liisa Eskelinen, Fanny Mochel, Michael Spedding, Caroline Louis, Olivier R. Martin, Mark J. Millan

Research output: Contribution to journalReview article

49 Citations (Scopus)

Abstract

Neurodegenerative disorders of ageing (NDAs) such as Alzheimer disease, Parkinson disease, frontotemporal dementia, Huntington disease and amyotrophic lateral sclerosis represent a major socio-economic challenge in view of their high prevalence yet poor treatment. They are often called ‘proteinopathies’ owing to the presence of misfolded and aggregated proteins that lose their physiological roles and acquire neurotoxic properties. One reason underlying the accumulation and spread of oligomeric forms of neurotoxic proteins is insufficient clearance by the autophagic–lysosomal network. Several other clearance pathways are also compromised in NDAs: chaperone-mediated autophagy, the ubiquitin–proteasome system, extracellular clearance by proteases and extrusion into the circulation via the blood–brain barrier and glymphatic system. This article focuses on emerging mechanisms for promoting the clearance of neurotoxic proteins, a strategy that may curtail the onset and slow the progression of NDAs.

Original languageEnglish (US)
Pages (from-to)660-688
Number of pages29
JournalNature Reviews Drug Discovery
Volume17
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Neurodegenerative Diseases
Frontotemporal Dementia
Proteins
Huntington Disease
Autophagy
Amyotrophic Lateral Sclerosis
Parkinson Disease
Alzheimer Disease
Peptide Hydrolases
Economics

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Boland, B., Yu, W. H., Corti, O., Mollereau, B., Henriques, A., Bezard, E., ... Millan, M. J. (2018). Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. Nature Reviews Drug Discovery, 17(9), 660-688. https://doi.org/10.1038/nrd.2018.109

Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. / Boland, Barry; Yu, Wai Haung; Corti, Olga; Mollereau, Bertrand; Henriques, Alexandre; Bezard, Erwan; Pastores, Greg M.; Rubinsztein, David C.; Nixon, Ralph A.; Duchen, Michael R.; Mallucci, Giovanna R.; Kroemer, Guido; Levine, Beth; Eskelinen, Eeva Liisa; Mochel, Fanny; Spedding, Michael; Louis, Caroline; Martin, Olivier R.; Millan, Mark J.

In: Nature Reviews Drug Discovery, Vol. 17, No. 9, 01.09.2018, p. 660-688.

Research output: Contribution to journalReview article

Boland, B, Yu, WH, Corti, O, Mollereau, B, Henriques, A, Bezard, E, Pastores, GM, Rubinsztein, DC, Nixon, RA, Duchen, MR, Mallucci, GR, Kroemer, G, Levine, B, Eskelinen, EL, Mochel, F, Spedding, M, Louis, C, Martin, OR & Millan, MJ 2018, 'Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing', Nature Reviews Drug Discovery, vol. 17, no. 9, pp. 660-688. https://doi.org/10.1038/nrd.2018.109
Boland, Barry ; Yu, Wai Haung ; Corti, Olga ; Mollereau, Bertrand ; Henriques, Alexandre ; Bezard, Erwan ; Pastores, Greg M. ; Rubinsztein, David C. ; Nixon, Ralph A. ; Duchen, Michael R. ; Mallucci, Giovanna R. ; Kroemer, Guido ; Levine, Beth ; Eskelinen, Eeva Liisa ; Mochel, Fanny ; Spedding, Michael ; Louis, Caroline ; Martin, Olivier R. ; Millan, Mark J. / Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. In: Nature Reviews Drug Discovery. 2018 ; Vol. 17, No. 9. pp. 660-688.
@article{dc5eb32e3aff485482ca060064042be8,
title = "Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing",
abstract = "Neurodegenerative disorders of ageing (NDAs) such as Alzheimer disease, Parkinson disease, frontotemporal dementia, Huntington disease and amyotrophic lateral sclerosis represent a major socio-economic challenge in view of their high prevalence yet poor treatment. They are often called ‘proteinopathies’ owing to the presence of misfolded and aggregated proteins that lose their physiological roles and acquire neurotoxic properties. One reason underlying the accumulation and spread of oligomeric forms of neurotoxic proteins is insufficient clearance by the autophagic–lysosomal network. Several other clearance pathways are also compromised in NDAs: chaperone-mediated autophagy, the ubiquitin–proteasome system, extracellular clearance by proteases and extrusion into the circulation via the blood–brain barrier and glymphatic system. This article focuses on emerging mechanisms for promoting the clearance of neurotoxic proteins, a strategy that may curtail the onset and slow the progression of NDAs.",
author = "Barry Boland and Yu, {Wai Haung} and Olga Corti and Bertrand Mollereau and Alexandre Henriques and Erwan Bezard and Pastores, {Greg M.} and Rubinsztein, {David C.} and Nixon, {Ralph A.} and Duchen, {Michael R.} and Mallucci, {Giovanna R.} and Guido Kroemer and Beth Levine and Eskelinen, {Eeva Liisa} and Fanny Mochel and Michael Spedding and Caroline Louis and Martin, {Olivier R.} and Millan, {Mark J.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1038/nrd.2018.109",
language = "English (US)",
volume = "17",
pages = "660--688",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing

AU - Boland, Barry

AU - Yu, Wai Haung

AU - Corti, Olga

AU - Mollereau, Bertrand

AU - Henriques, Alexandre

AU - Bezard, Erwan

AU - Pastores, Greg M.

AU - Rubinsztein, David C.

AU - Nixon, Ralph A.

AU - Duchen, Michael R.

AU - Mallucci, Giovanna R.

AU - Kroemer, Guido

AU - Levine, Beth

AU - Eskelinen, Eeva Liisa

AU - Mochel, Fanny

AU - Spedding, Michael

AU - Louis, Caroline

AU - Martin, Olivier R.

AU - Millan, Mark J.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Neurodegenerative disorders of ageing (NDAs) such as Alzheimer disease, Parkinson disease, frontotemporal dementia, Huntington disease and amyotrophic lateral sclerosis represent a major socio-economic challenge in view of their high prevalence yet poor treatment. They are often called ‘proteinopathies’ owing to the presence of misfolded and aggregated proteins that lose their physiological roles and acquire neurotoxic properties. One reason underlying the accumulation and spread of oligomeric forms of neurotoxic proteins is insufficient clearance by the autophagic–lysosomal network. Several other clearance pathways are also compromised in NDAs: chaperone-mediated autophagy, the ubiquitin–proteasome system, extracellular clearance by proteases and extrusion into the circulation via the blood–brain barrier and glymphatic system. This article focuses on emerging mechanisms for promoting the clearance of neurotoxic proteins, a strategy that may curtail the onset and slow the progression of NDAs.

AB - Neurodegenerative disorders of ageing (NDAs) such as Alzheimer disease, Parkinson disease, frontotemporal dementia, Huntington disease and amyotrophic lateral sclerosis represent a major socio-economic challenge in view of their high prevalence yet poor treatment. They are often called ‘proteinopathies’ owing to the presence of misfolded and aggregated proteins that lose their physiological roles and acquire neurotoxic properties. One reason underlying the accumulation and spread of oligomeric forms of neurotoxic proteins is insufficient clearance by the autophagic–lysosomal network. Several other clearance pathways are also compromised in NDAs: chaperone-mediated autophagy, the ubiquitin–proteasome system, extracellular clearance by proteases and extrusion into the circulation via the blood–brain barrier and glymphatic system. This article focuses on emerging mechanisms for promoting the clearance of neurotoxic proteins, a strategy that may curtail the onset and slow the progression of NDAs.

UR - http://www.scopus.com/inward/record.url?scp=85053082981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053082981&partnerID=8YFLogxK

U2 - 10.1038/nrd.2018.109

DO - 10.1038/nrd.2018.109

M3 - Review article

C2 - 30116051

AN - SCOPUS:85053082981

VL - 17

SP - 660

EP - 688

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 9

ER -